The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
Open accessPublished version of a preprint
Abstract
Natural killer (NK) cells are immune cells sensing and eliminating foreign, stressed, transformed, and senescent cells through specialized surface receptors, such as NKG2D, that interacts with several virus- or stress-inducible ligands, including ULBP1 and -2, which are expressed on target cell surfaces. For example, induction of DNA damage or cellular senescence pathways in tumor cells led to upregulation of NKG2D ligands that activate NK cells. Although, both pathways activate p53, the relationship of p53 activation to upregulation of NKG2D ligands has not been addressed. In this study, we report that induction of wild-type p53, but not mutant p53, strongly upregulated mRNA and cell surface expression of ULBP1 and -2, whereas expression of other NK cell ligands was not affected. We defined intronic p53-responsive elements in these two novel p53 target genes. Coculture of wild-type p53-induced human tumor cells with primary human NK cells enhanced NKG2D-dependent degranulation and IFN-γ production by NK cells. Accordingly, treatment of certain wild-type p53-expressing tumor cell lines with the p53-reactivating small molecular compound RITA resulted in upregulation of ULBP2 mRNA and cell surface protein expression. Taken together, our findings define the involvement of p53 in the regulation of specific NKG2D ligands that enhance NK cell–mediated target recognition. One implication of our work is that activating p53 after adoptive transfer of NK cells might constitute an effective combinatorial strategy of NK cell–based immunochemotherapy in cancers in which wild-type p53 function is preserved. Cancer Res; 71(18); 5998–6009. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In brief, the status of genes can influence tumor cells not only through the impact of wild-type gene loss but also through their effects on the TIME.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“Some missense mutant proteins can lose the transcriptional effects of wild-type genes, such as keeping PDL1 expression levels low, thereby making cancer cells more susceptible to cytotoxic T cells and NK cells, limiting the immune system’s ability to attack cancer cells.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“On the other hand, activating wild-type proteins can increase IFNγ signaling and sensitize tumors to immune checkpoint inhibitors, whereas corresponding mutant proteins can reduce the efficacy of immune checkpoint inhibitors.612–614”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“In contrast, two studies reported that pharmacological reactivation of p53 in specific cell lines can stimulate the expression of ULPB2, a ligand for human NKG2D (Li et al., 2011; Textor et al., 2011).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Textor et al., 2011
In the citing paper
“Additional immunostimulatory effects linked to pharmacological p53 reactivation in cancer cells include (but are not limited to) (1) downregulation of immunomodulatory cytokines linked to tumor progression, such as IL6 (Sahin et al., 2020); (2) upregulation of NKALs (Textor et al., 2011); and (3) establishment of cellular senescence linked to an immunostimulatory SASP that favors the recruitment”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Textor et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Recently, it has been shown that reactivation of p53 in mouse cancer models induced rapid tumor regression by the induction of apoptosis or cellular senescence depending on the tumor type (5).”
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J. D., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,674
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W. A., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,394
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
Martin‐Fontecha, A., Thomsen, L. L., Brett, S. J., Gerard, C. J., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2004) · Nature Immunology · doi:10.1038/ni1138 · Cited by 1,351
Cited by
Sorted by citations
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 877
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 622
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2016) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 523
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N. T., & Raulet, D. H. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 410
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Muñoz‐Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.99 · Cited by 344
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Xiao, Y., Chen, J., Zhou, H., Zeng, X., Ruan, Z., Pu, Z., Jiang, X., Matsui, A., Zhu, L., Amoozgar, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28279-8 · Cited by 269
NKG2D and Its Ligands: “One for All, All for One”
Zingoni, A., Molfetta, R., Fionda, C., Soriani, A., Paolini, R., Cippitelli, M., Cerboni, C., & Santoni, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00476 · Cited by 267
Natural killer group 2D receptor and its ligands in cancer immune escape
Duan, S., Guo, W., Xu, Z., He, Y., Liang, C., Mo, Y., Wang, Y., Xiong, F., Guo, C. J., Li, Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0956-8 · Cited by 248
Schlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose‐John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E. P., Textor, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3017 · Cited by 216
Self-citationMolecular mechanisms of natural killer cell activation in response to cellular stress
Chan, C. J., Smyth, M. J., & Martinet, L. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.26 · Cited by 222
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Immune-suppressive properties of the tumor microenvironment
Becker, J. C., Andersen, M. H., Schrama, D., & Straten, P. T. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1434-6 · Cited by 211
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 208
Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 189
Zhang, L., Zhao, J., Hu, X., Wang, C., Jia, Y., Zhu, C., Xie, S., Lee, J., Li, F., & Ling, D. (2022) · Advanced Materials · doi:10.1002/adma.202206915 · Cited by 181
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
Schmiedel, D., & Mandelboim, O. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02040 · Cited by 174
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162
The effect of environmental chemicals on the tumor microenvironment
Casey, S. C., Vaccari, M., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., Barcellos‐Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv035 · Cited by 159
Cancer type-dependent correlations between TP53 mutations and antitumor immunity
Li, L., Li, M., & Wang, X. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102785 · Cited by 152
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Mazzone, R., Zwergel, C., Mai, A., & Valente, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0358-y · Cited by 151
Pateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 147
Natural Killer cells at the frontline in the fight against cancer
Coënon, L., Geindreau, M., Ghiringhelli, F., Villalba, M., & Bruchard, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06976-0 · Cited by 168
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 143
Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer
Jiang, Z., Liu, Z., Li, M., Chen, C., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.07.012 · Cited by 136
Inhibition of p53 inhibitors: progress, challenges and perspectives
Sanz, G., Singh, M., Peuget, S., & Selivanova, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz075 · Cited by 140
Lyu, H., Li, M., Jiang, Z., Liu, Z., & Wang, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.07.009 · Cited by 137
NKG2D signaling in cancer immunosurveillance
López‐Soto, A., Huergo-Zapico, L., Acebes‐Huerta, A., Villa-Álvarez, M., & Gonzalez, S. R. (2014) · International Journal of Cancer · doi:10.1002/ijc.28775 · Cited by 138
Cerboni, C., Fionda, C., Soriani, A., Zingoni, A., Doria, M., Cippitelli, M., & Santoni, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00508 · Cited by 141
Fiegler, N., Textor, S., Arnold, A., Rölle, A., Oehme, I., Breuhahn, K., Moldenhauer, G., Witzens‐Harig, M., & Cerwenka, A. (2013) · Blood · doi:10.1182/blood-2013-02-482513 · Cited by 135
Self-citationCui, Y. R., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 137
Jung, H., Hsiung, B., Pestal, K., Procyk, E., & Raulet, D. H. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120565 · Cited by 123
Liu, Y., Zhang, X., Zhang, J., Tan, J., Li, J., & Song, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.2139/ssrn.3678770 · Cited by 126
Genetics, genomics, and evolutionary biology of NKG 2D ligands
Carapito, R., & Bahram, S. (2015) · Immunological Reviews · doi:10.1111/imr.12328 · Cited by 125
New prospects on the NKG2D/NKG2DL system for oncology
Ullrich, E., Koch, J., Cerwenka, A., & Steinle, A. (2013) · OncoImmunology · doi:10.4161/onci.26097 · Cited by 119
Self-citationInteractions between the tumor suppressor p53 and immune responses
Menéndez, D., Shatz, M., & Resnick, M. A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6386 · Cited by 115
The DNA Damage Response and Inflammation in Cancer
Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 115
Immunosurveillance and immunotherapy of tumors by innate immune cells
Iannello, A., Thompson, T. W., Ardolino, M., Marcus, A., & Raulet, D. H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.11.001 · Cited by 105
Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
Orentas, R. J., Yang, J. J., Wen, X., Wei, J. S., Mackall, C. L., & Khan, J. I. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00194 · Cited by 104
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
Raneros, A. B., Martín‐Palanco, V., Fernández, A. F., Rodríguez, R. M. A., Fraga, M. F., López‐Larrea, C., & Suárez-Álvarez, B. (2014) · Genes and Immunity · doi:10.1038/gene.2014.58 · Cited by 101
P53: A Guardian of Immunity Becomes Its Saboteur through Mutation
Agupitan, A. D., Neeson, P. J., Williams, S., Howitt, J. A., Haupt, S., & Haupt, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103452 · Cited by 111
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
Soriani, A., Iannitto, M. L., Ricci, B., Fionda, C., Malgarini, G., Morrone, S., Peruzzi, G., Ricciardi, M. R., Petrucci, M. T., Cippitelli, M., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400271 · Cited by 98
The role of p53 in anti-tumor immunity and response to immunotherapy
Carlsen, L., Zhang, S., Tian, X., Cruz, A. D. L., George, A., Arnoff, T. E., & El‐Deiry, W. S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1148389 · Cited by 96
TP53 Mutations Promote Immunogenic Activity in Breast Cancer
Liu, Z., Jiang, Z., Gao, Y., Wang, L., Chen, C., & Wang, X. (2018) · Journal of Oncology · doi:10.1155/2019/5952836 · Cited by 90
Kang, D. Y., Sp, N., Jo, E. S., Rugamba, A., Hong, D. Y., Lee, M. H., Yoo, J., Liu, Q., Jang, K., & Yang, Y. M. (2020) · Cancers · doi:10.3390/cancers12030727 · Cited by 86
Lai, H., Zeng, D., Liu, C., Zhang, Q., Wang, X., & Chen, T. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119377 · Cited by 75
Shaping of NK Cell Responses by the Tumor Microenvironment
Stojanovic, A., Correia, M. P., & Cerwenka, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0125-8 · Cited by 96
Self-citationA Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development
Shi, D., & Jiang, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762651 · Cited by 84
Immunobiology and Conflicting Roles of the Human NKG2D Lymphocyte Receptor and Its Ligands in Cancer
El‐Gazzar, A., Groh, V., & Spies, T. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301071 · Cited by 85
Fionda, C., Soriani, A., Zingoni, A., Santoni, A., & Cippitelli, M. (2015) · BioMed Research International · doi:10.1155/2015/178698 · Cited by 72
p53: From Fundamental Biology to Clinical Applications in Cancer
Capuozzo, M., Santorsola, M., Bocchetti, M., Perri, F., Cascella, M., Granata, V., Celotto, V., Gualillo, O., Cossu, A. M., Nasti, G., et al. (2022) · Biology · doi:10.3390/biology11091325 · Cited by 74
Nanbakhsh, A., Pochon, C., Mallavialle, A., Amsellem, S., Bourhis, J. H., & Chouaı̈b, S. (2014) · Blood · doi:10.1182/blood-2013-11-536219 · Cited by 68
Wood, W. A., Krishnamurthy, J., Mitin, N., Torrice, C., Parker, J. S., Snavely, A. C., Shea, T. C., Serody, J. S., & Sharpless, N. E. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.029 · Cited by 73
Molecular Bases for the Regulation of NKG2D Ligands in Cancer
Huergo-Zapico, L., Acebes‐Huerta, A., López‐Soto, A., Villa-Ãlvarez, M. N., González, A. P., & Gonzalez, S. R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00106 · Cited by 66
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 68
Raulet, D. H., Marcus, A., & Coscoy, L. (2017) · Immunological Reviews · doi:10.1111/imr.12600 · Cited by 66
Advances in NKG2D ligand recognition and responses by NK cells
Bert, N. L., & Gasser, S. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2013.111 · Cited by 63
Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression
Jones, A. B., Rocco, A., Lamb, L. S., Friedman, G. K., & Hjelmeland, A. B. (2022) · Cancers · doi:10.3390/cancers14092339 · Cited by 66
Strategies to improve the immunosuppressive properties of human mesenchymal stem cells
Lee, M. W., Ryu, S., Kim, D. S., Sung, K. W., Koo, H. H., & Yoo, K. H. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0178-y · Cited by 61
Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy
Liu, Y. U., Leslie, P. L., & Zhang, Y. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.005 · Cited by 61
TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications
Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S. (2024) · Cancers · doi:10.3390/cancers16173069 · Cited by 70
The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells
Textor, S., Bossler, F., Henrich, K., Gartlgruber, M., Pollmann, J., Fiegler, N., Arnold, A., Westermann, F., Waldburger, N., Breuhahn, K., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1116674 · Cited by 56
Self-citationRegulation of NKG2D Expression and Signaling by Endocytosis
Molfetta, R., Quatrini, L., Zitti, B., Capuano, C., Galandrini, R., Santoni, A., & Paolini, R. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.015 · Cited by 59
Brandetti, E., Veneziani, I., Melaiu, O., Pezzolo, A., Castellano, A., Boldrini, R., Ferretti, E., Fruci, D., Moretta, L., Pistoia, V., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1316439 · Cited by 56
Immunosurveillance as a regulator of tissue homeostasis
Senovilla, L., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.06.005 · Cited by 57
Gowen, B. G., Chim, B., Marceau, C. D., Greene, T. T., Burr, P., Gonzalez, J. R., Hesser, C. R., Dietzen, P. A., Russell, T. A., Iannello, A., et al. (2015) · eLife · doi:10.7554/elife.08474 · Cited by 52
El‐Jawhari, J. J., El-Sherbiny, Y. M., Scott, G. B., Morgan, R. S. M., Prestwich, R. J. D., Bowles, P. A., Blair, G. E., Tanaka, T. U., Rabbitts, T. H., Meade, J. L., et al. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.020 · Cited by 54
Immune Surveillance of Unhealthy Cells by Natural Killer CellsPreprint
Iannello, A., & Raulet, D. H. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.020255 · Cited by 60
Virus-mediated inhibition of natural cytotoxicity receptor recognition
Seidel, E., Glasner, A., & Mandelboim, O. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1001-x · Cited by 54
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Cifaldi, L., Locatelli, F., Marasco, E., Moretta, L., & Pistoia, V. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.002 · Cited by 51
The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
Tan, G., Spillane, K. M., & Maher, J. F. (2023) · Biology · doi:10.3390/biology12081079 · Cited by 56
Veneziani, I., Infante, P., Ferretti, E., Melaiu, O., Battistelli, C., Lucarini, V., Compagnone, M., Nicoletti, C., Castellano, A., Petrini, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0313 · Cited by 48
Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 46
Guo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 47
Sottile, R., Pangigadde, P., Tan, T., Anichini, A., Sabbatino, F., Trecroci, F., Favoino, E., Orgiano, L., Roberts, J. T., Ferrone, S., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201445289 · Cited by 40
Deng, S., Wang, M., Wang, C., Zeng, Y., Qin, X. Y., Tan, Y., Liang, B., & Cao, Y. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08047-z · Cited by 38
Dying to Survive—The p53 Paradox
Lees, A., Sessler, T., & McDade, S. S. (2021) · Cancers · doi:10.3390/cancers13133257 · Cited by 38
Immune and inflammatory responses to DNA damage in cancer and aging
Soria‐Valles, C., López‐Soto, A., Osorio, F. G., & López-Otín, C. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.10.004 · Cited by 36
Hosomi, S., Grootjans, J., Huang, Y., Kaser, A., & Blumberg, R. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01324 · Cited by 35
Soriani, A., Borrelli, C., Ricci, B., Molfetta, R., Zingoni, A., Fionda, C., Carnevale, S., Abruzzese, M. P., Petrucci, M. T., Ricciardi, M. R., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1264564 · Cited by 34
CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells
Sauer, M., Schuldner, M., Hoffmann, N., Çetintaş, A., Reiners, K., Shatnyeva, O., Hallek, M., Hansen, H., Gasser, S., & von Strandmann, E. P. (2016) · Oncogene · doi:10.1038/onc.2016.259 · Cited by 36
Focaccetti, C., Benvenuto, M., Pighi, C., Vitelli, A., Napolitano, F., Cotugno, N., Fruci, D., Palma, P., Rossi, P., Bei, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886319 · Cited by 33
Paschen, A., Baingo, J., & Schadendorf, D. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2014.01.009 · Cited by 33
Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells
Bugide, S., Janoštiak, R., & Wajapeyee, N. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.06.004 · Cited by 30
Regulation of self-ligands for activating natural killer cell receptors
Lam, R. A., Chwee, J. Y., Bert, N. L., Sauer, M., von Strandmann, E. P., & Gasser, S. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.792495 · Cited by 32
Medrano, R. F. V., Catani, J. P. P., Hunger, A., Tomaz, S. L., Merkel, C. A., Costanzi-Strauss, E., & Strauss, B. E. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1807-8 · Cited by 31
Dinavahi, S. S., Chen, Y., Punnath, K., Berg, A. S., Herlyn, M., Foroutan, M., Huntington, N. D., & Robertson, G. P. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0587 · Cited by 31
The Wheel of p53 Helps to Drive the Immune System
Łasut-Szyszka, B., & Rusin, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087645 · Cited by 31
Xia, Y., Du, Z., Wang, X., & Li, X. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.206 · Cited by 32
Modulation of immune responses by the tumor suppressor p53
Lowe, J. M., Shatz, M., Resnick, M. A., & Menéndez, D. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.2 · Cited by 30
The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment
Sun, H., Zhang, B., & Li, H. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820920969 · Cited by 28
Chauhan, S., Jaiswal, S., Jakhmola, V., Singh, B. P., Bhattacharya, S., Garg, M., & Sengupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216766 · Cited by 29
Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217614 · Cited by 27
Metadata
- Authors
- Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Corresponding author
- Cerwenka, Adelheid
- Venue
- Cancer Research
- Published
- 2011-09-13
- Volume
- 71
- Issue
- 18
- Pages
- 5998-6009
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2123143632
- Cited by
- 221
- References
- 36
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 13 · 2022: 18 · 2021: 13 · 2020: 19 · 2019: 11 · 2018: 12 · 2017: 10 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 20 · 2012: 13
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- natural killer cells, NKG2D ligands, ULBP1, ULBP2, p53, wild-type p53, p53 target genes, p53 response elements, NK cell cytotoxicity, interferon-gamma, RITA, p53 reactivation
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Furans, Humans, Introns, Killer Cells, Natural, Lung Neoplasms, RNA, Messenger, Up-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, NK Cell Lectin-Like Receptor Subfamily K, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
